Valuation: Imugene Limited

Market Cap 35.35M 24.81M 21.57M 20.08M 18.43M 34.81M 2.37B 237M 92.87M 1.18B 93.18M 91.13M 3.95B P/E 2026 *
-0.73x
P/E 2027 * -1.08x
Enterprise Value 35.05M 24.6M 21.39M 19.91M 18.28M 34.51M 2.35B 235M 92.08M 1.17B 92.39M 90.36M 3.92B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day+2.41%
1 week-5.56%
1 month-39.29%
3 months-22.73%
6 months-69.64%
Current year-76.71%
1 week 0.08
Extreme 0.083
0.09
1 month 0.08
Extreme 0.083
0.11
Current year 0.08
Extreme 0.083
0.41
1 year 0.08
Extreme 0.083
0.46
3 years 0.08
Extreme 0.083
5.1
5 years 0.08
Extreme 0.083
21.25
10 years 0.08
Extreme 0.083
21.25
Manager TitleAgeSince
Director of Finance/CFO - 04/03/2025
Chief Tech/Sci/R&D Officer - 01/09/2023
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 70 31/10/2012
Director/Board Member 66 23/04/2019
Director/Board Member 61 07/09/2022
Date Insider Type Main position Quantity % Market Cap.
12/19/25 A Free

Director

14,706 0.0047%
12/19/25 A Free

Director

29,411 0.0093%
12/19/25 A Fiscal year

Director

14,706 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%-5.56%-66.00%-97.50% 24.81M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+36.40%+125.75% 16.11B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.11%+0.39%+47.92%+68.40% 25.04B
Weighted average by Cap. -1.60%+2.03%+79.77%+108.59%

Financials

2026 *2027 *
Net sales - -
Net income -56.51M -39.67M -34.48M -32.09M -29.47M -55.65M -3.79B -378M -148M -1.89B -149M -146M -6.32B -42.79M -30.03M -26.11M -24.3M -22.31M -42.13M -2.87B -286M -112M -1.43B -113M -110M -4.79B
Net Debt -300K -211K -183K -170K -156K -295K -20.1M -2.01M -788K -10.01M -791K -774K -33.56M -1M -702K -610K -568K -521K -985K -67.01M -6.69M -2.63M -33.36M -2.64M -2.58M -112M
Logo Imugene Limited
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Employees
15
Date Price Change Volume
31/07/26 A$0.0850 +2.41% 1,660,695
30/07/26 A$0.0830 -2.35% 2,496,874
29/07/26 A$0.0850 -1.16% 2,598,603
28/07/26 A$0.0860 -4.44% 5,071,152
27/07/26 A$0.0900 -.--% 4,228,650
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0850AUD
Average target price
0.3067AUD
Spread / Average Target
+260.79%

Quarterly revenue - Rate of surprise